Naltrexone and Buprenorphine Market Size, Share, Trends, Industry Analysis Report By Product (Naltrexone, Buprenorphine), By Route of Administration, By Application, By Distribution Channel, By Region – Market Forecast, 2025–2034

The naltrexone and buprenorphine market size is expected to reach USD 12.40 billion by 2034, according to a new study by Polaris Market Research. The report “Naltrexone and Buprenorphine Market Size, Share, Trends, Industry Analysis Report By Product (Naltrexone, Buprenorphine), By Route of Administration, By Application, By Distribution Channel, By Region– Market Forecast, 2025–2034” gives a detailed insight into current market dynamics and provides analysis on future market growth.

Naltrexone and buprenorphine are medications used to treat opioid use disorder by reducing cravings and preventing relapse. There is a shift in how opioid use disorder is being treated from short-term detox to long-term recovery planning. Healthcare professionals now recognize that continued medication support can improve recovery outcomes and lower relapse risks. Naltrexone and buprenorphine are both used in long-term treatment strategies because they help people stay engaged in care and reduce the chance of returning to drug use. As more treatment centers adopt a long-term approach, the need for medications that can be taken safely over time increases. This trend supports continued growth in the use of both medications across various care settings.

Traditionally, treatment for opioid use disorder was handled mostly by addiction specialists, but this is changing. Now, more primary care providers and general practitioners are offering medication-assisted treatment using naltrexone and buprenorphine. This is partly due to reduced prescribing restrictions and increased training for non-specialists. Patients can now receive treatment from their regular doctors, making it easier to access care. This shift is helping integrate OUD treatment into everyday healthcare, which increases the number of patients who can start and continue treatment. As access widens, use of these medications is expected to keep rising.

Naltrexone and Buprenorphine Market Report Highlights

In 2024, the buprenorphine segment dominated with a larger share due to its widespread use in managing opioid withdrawal symptoms and reducing cravings.

The hospitals pharmacies segment is expected to experience significant growth during the forecast period, as hospitals are the first point of care for individuals experiencing overdose or withdrawal.

In 2024, North America dominated the naltrexone and buprenorphine market with the largest share driven by the high prevalence of opioid use disorder and strong government involvement in expanding access to treatment.

The Asia Pacific naltrexone and buprenorphine market is experiencing significant growth, due to growing awareness of substance use disorders and efforts to strengthen mental health services.

A few global key market players are Alkermes, Inc.; Camurus; Collegium Pharmaceutical; Indivior PLC; Orexo US, Inc. (a part of Orexo AB); Sun Pharmaceutical Industries Ltd; and Titan Pharmaceuticals, Inc.

Polaris market research has segmented the naltrexone and buprenorphine market report based on product, route of administration, application, distribution channel, and region:

By Product (Revenue – USD Billion, 2020–2034)

Naltrexone

Buprenorphine

BELBUCA

Sublocade

Suboxone

Zubsolv

Others

By Route of Administration (Revenue – USD Billion, 2020–2034)

Oral Administration

Injectable Administration

Implantable Administration

By Application (Revenue – USD Billion, 2020–2034)

Opioid Use Disorder (OUD)

Alcohol Use Disorder (AUD)

By Distribution Channel (Revenue – USD Billion, 2020–2034)

Hospitals Pharmacies

Retail Pharmacies

Others

By Regional Outlook (Revenue – USD Billion, 2020–2034)

North America

U.S.

Canada

Mexico

Europe

Germany

UK

France

Italy

Spain

Russia

Netherlands

Rest of Europe

Asia Pacific

China

India

Japan

South Korea

Indonesia

Malaysia

Australia

Rest of APAC

Latin America

Argentina

Brazil

Rest of Latin America

Middle East & Africa

UAE

Saudi Arabia

Israel

South Africa

Rest of MEA Show more